A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia

@article{Zannolli2012ART,
  title={A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia},
  author={Raffaella Zannolli and Sabrina Buoni and Gianni Betti and Sara Salvucci and Alessandro Plebani and Annarosa Soresina and Maria Cristina Pietrogrande and S. Martino and Vincenzo Leuzzi and Andrea Finocchi and Roberto Micheli and Livia N. Rossi and Alfredo Brusco and Filippo Misiani and Alberto Fois and Joseph Hayek and Colleen Kelly and Luciana Chessa},
  journal={Movement Disorders},
  year={2012},
  volume={27}
}
No controlled studies exist regarding the pharmaceutical reduction of ataxia symptoms in ataxia telangiectasia (A‐T). In a multicenter, double‐blind, randomized, placebo‐controlled crossover trial, oral betamethasone (BETA) and placebo were compared in terms of their reduction of ataxia symptoms as assessed with the International Cooperative Ataxia Rating Scale (ICARS). In this study of 13 A‐T children, betamethasone reduced the ICARS total score by a median of 13 points in the intent‐to‐treat… 
Title : Minimum effective betamethasone dosage on the neurological phenotype in patients with Ataxia-Telangiectasia : a multicenter observer-blind study Running Title : Betamethasone treatment in Ataxia-Telangiectasia
TLDR
These data suggest that a short-term betamethasone oral treatment, at a daily dosage of 0.005 mg/kg/day, is effective in some patients, and pre-existing risk factors for sideeffects should be taken into account before therapy.
Minimum effective betamethasone dosage on the neurological phenotype in patients with ataxia‐telangiectasia: a multicenter observer‐blind study
TLDR
The aim of this multicenter study was to define the minimal effective dosage of oral betamethasone, thus preventing the occurrence of side effects, in patients with ataxia‐telangiectasia.
Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia
TLDR
Patients in the extended study experienced a continuous neurologic improvement with respect to their pretreatment status, whereas controls showed a progressive neurologic deterioration (according to the natural history of the disease) after the discontinuation of the treatment.
Betamethasone therapy in ataxia telangiectasia: unraveling the rationale of this serendipitous observation on the basis of the pathogenesis
TLDR
A better understanding of the mechanisms of action of GCs in the brain is needed, because in A‐T during the initial phase of cell loss the neurological impairment may be rescued by interfering in the biochemical pathways.
Intra-Erythrocyte Infusion of Dexamethasone Reduces Neurological Symptoms in Ataxia Teleangiectasia Patients: Results of a Phase 2 Trial
TLDR
EryDex treatment led to a significant improvement in neurological symptoms, without association with the typical steroid side effects, and a more marked improvement was found in less neurologically impaired patients.
Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials
TLDR
The placebo response in patients with CAs on various objective ataxia scales is demonstrated and it is emphasized that the placebo response should be considered when designing, analyzing, and interpreting clinical trials and in clinical practice in CA patients.
Ibuprofen prevents progression of ataxia telangiectasia symptoms in ATM-deficient mice
TLDR
While the behavioral symptoms could not be reversed once they were established in adult Atm−/− animals, administration of ibuprofen to young mutant pups prevented their symptoms from appearing, implying that modulation of the immune system can have therapeutic benefit for both the behavioral and cellular symptoms of this neurodegenerative disease.
Current and future therapeutic strategies to treat ataxia telangiectasia
TLDR
Efficacy of steroids in improving ataxia of AT patients is proven and encapsulation of the drug into erythrocytes followed by slow release appears promising, and extrapyramidal symptoms may be ameliorated by dopaminergic drugs.
Focusing New Ataxia Telangiectasia Therapeutic Approaches
TLDR
The classical and the new therapeutic approaches in ataxia Telangiectasia are discussed in the light of the most recent reports in the literature.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Steroid‐induced improvement of neurological signs in ataxia‐telangiectasia patients
TLDR
The data indicate that neurological signs in A‐T are susceptible of beneficial pharmacological intervention even years after the disease onset, and inversely correlated with the level of cerebellum atrophy, as revealed by the magnetic resonance.
Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia.
TLDR
Control studies to better understand the most appropriate drug and therapeutic schedule are required for corticosteroid therapy on the central nervous system symptoms of a child with ataxia-telangiectasia in whom neurological signs improved when, occasionally, he was given betamethasone to treat asthmatic bronchitis attacks.
Friedreich's ataxia: idebenone treatment in early stage patients.
TLDR
Idebenone treatment at early stages of the disease seems to reduce the progression of cerebellar manifestations and further blind trials with a greater number of patients and higher doses are needed to fully assess the therapeutic potential of idebenone in Friedreich's ataxia.
Efficacy of very‐low‐dose betamethasone on neurological symptoms in ataxia‐telangiectasia
TLDR
A recent study documented improvement in neurological symptoms after a short‐term therapy with betamethasone in patients with A‐T.
How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales
TLDR
The Friedreich Ataxia Rating Scale (FARS) is the best to use in clinical trials of FRDA based on effect size, and power calculations that show that fewer participants are required to demonstrate the same effect of an intervention.
In ataxia‐teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity
TLDR
The aim of this study was to define the underlying biochemical mechanism of A‐T, and documented a clear improvement of cerebellar functions during a short‐term betamethasone trial.
International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome
Comparison of three clinical rating scales in Friedreich ataxia (FRDA)
TLDR
Although originally developed for the use in dominantly inherited ataxias, SARA can also be used successfully to assess afferent ataxia, which is the predominant form in FRDA and is well suited forclinical trials of FRDA.
Neurophysiological evaluation in children with Friedreich's ataxia.
International cooperative ataxia rating scale (ICARS): Appropriate for studies of Friedreich's ataxia?
TLDR
The ICARS total score effectively satisfied all psychometric criteria tested, and the extent to which this score quantifies the true extent of FRDA remains uncertain as the validity testing was limited, partly by the lack of appropriate validating measures.
...
1
2
3
4
...